News >

CDK4/6 Inhibitors Changing Course of Care in HR+/HER2- Breast Cancer

Caroline Seymour
Published: Friday, Feb 08, 2019

Neelima Denduluri, MD

Neelima Denduluri, MD

Earlier diagnosis and more effective therapeutic options are enabling physicians to deliver better rates of disease control and improved quality of life (QoL) to patients with hormone receptor (HR)–positive, HER2-negative metastatic breast cancer, explained Neelima Denduluri, MD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Where Are We Headed in the Treatment of Triple-Negative Breast Cancer?Jul 31, 20191.5
Community Practice Connections™: Evolving Applications for PARP Inhibitors in Ovarian Cancer: Building on a Solid FoundationAug 15, 20191.5
Publication Bottom Border
Border Publication
x